Clinical Trials Logo

Clinical Trial Summary

The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).


Clinical Trial Description

The Anti-Aβ mAb CED Study is conducted in accordance with the coverage criteria specified in the NCD for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia. The complete NCD decision memorandum is available on our website (https://www.cms.gov/medicare-coverage-database/view/ncacal-decisionmemo.aspx?proposed=N&ncai d=305). Study Overview: 1. Clinicians will conduct a neurocognitive evaluation to determine patient eligibility by confirming a clinical diagnosis of MCI due to AD or mild AD dementia, and the presence of amyloid using biomarker testing including imaging (amyloid PET), cerebral spinal fluid (CSF) studies, and/or blood tests. 2. For all Medicare beneficiaries receiving anti-Aβ mAb treatment for MCI due to AD or mild AD dementia, the prescribing clinician will assess the patient's baseline clinical status by cognition and function assessments using validated tools appropriate for use in the MCI with AD and mild AD dementia populations and submit these data to the registry via the dedicated CMS CED submission portal every six months for up to 24 months (five total assessments). 3. In addition to performing the required cognition and function assessments, prescribing clinicians will need to report on the patient's use of anti-platelet and/or anti-coagulation therapy and whether the patient has developed new amyloid related imaging abnormalities (ARIA) since the last assessment data submission. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06058234
Study type Observational
Source Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Contact CMS CAG
Phone 410-786-2281
Email CMS_caginquiries@cms.hhs.gov
Status Recruiting
Phase
Start date July 6, 2023
Completion date June 30, 2029

See also
  Status Clinical Trial Phase
Completed NCT00243451 - Early Detection of Mild Cognitive Impairment in Individual Patients N/A
Recruiting NCT05872243 - pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD) N/A
Recruiting NCT05417555 - Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease N/A
Terminated NCT01482013 - Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease Phase 1
Completed NCT03186989 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT03752294 - A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age. Phase 1
Completed NCT01013610 - An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease Phase 1
Active, not recruiting NCT03234686 - Deferiprone to Delay Dementia (The 3D Study) Phase 2
Completed NCT05233774 - Lomecel-B Effects on Alzheimer's Disease Phase 2
Withdrawn NCT05032482 - WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease N/A
Terminated NCT00582855 - Effect of AQW051 in Patients With Memory Impairment Phase 2
Completed NCT01061489 - Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment N/A
Completed NCT01548287 - A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment Phase 2
Terminated NCT00706186 - Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients Phase 4